[{"orgOrder":0,"company":"Kaneka Corporation","sponsor":"Kaneka Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Lactobacillus Plantarum (Cect7484 And Cect7485)","moa":"Undisclosed","graph1":"Neurology","graph2":"Undisclosed","graph3":"Kaneka Corporation","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kaneka Corporation \/ Kaneka Corporation","highestDevelopmentStatusID":"1","companyTruncated":"Kaneka Corporation \/ Kaneka Corporation"}]

Find Clinical Drug Pipeline Developments & Deals by Kaneka Corporation

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Aus. Peptide Conference
                          Not Confirmed
                          Aus. Peptide Conference
                          Not Confirmed

                          Lead Product(s) : Lactobacillus Plantarum (Cect7484 And Cect7485)

                          Therapeutic Area : Neurology

                          Study Phase : Undisclosed

                          Recipient : Scripps Health

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Lactobacillus Plantarum (Cect7484 And Cect7485) is a drug candidate, which is currently being evaluated in clinical studies for the treatment of Migraine Disorders.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          January 06, 2021

                          Lead Product(s) : Lactobacillus Plantarum (Cect7484 And Cect7485)

                          Therapeutic Area : Neurology

                          Highest Development Status : Undisclosed

                          Recipient : Scripps Health

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank